Switzerland · Delayed Price · Currency is CHF | Market Cap | 217.47B |
| Revenue (ttm) | 63.49B |
| Net Income (ttm) | 9.43B |
| Shares Out | n/a |
| EPS (ttm) | 11.74 |
| PE Ratio | 23.06 |
| Forward PE | 13.43 |
| Dividend | 9.70 (3.63%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 25,701 |
| Average Volume | 25,785 |
| Open | 266.00 |
| Previous Close | 267.20 |
| Day's Range | 265.00 - 268.40 |
| 52-Week Range | 244.00 - 333.60 |
| Beta | 0.18 |
| RSI | 38.27 |
| Earnings Date | Oct 20, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche points to U.S. plans after Trump pharma tariff announcement
Switzerland's Roche on Friday pointed to the fact that one of its U.S. units broke ground on a new facility in August and that the pharma company had pledged major U.S. investments after President Don...
Kodiak gains as Barclays upgrades on Roche data for eye disease drug
Kodiak Sciences (KOD) stock gains as Barclays upgrades the company, citing a positive read-through from a recent trial readout from Roche (RHHBY). Read more here.
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Roche Pharmaceuticals' CEO told investors she was "serious" about the goal of becoming a top 3 obesity player.
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Con...
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus® (ocrelizumab) and the investigational Bruton's tyrosin...
Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon?
Swiss pharmaceutical and diagnostics giant Roche Holding has finally released some positive news about its oral breast cancer drug giredestrant, which...
Roche Holding AG - Special Call
Roche Targets Top Spot In Weight Loss Drug Market
Roche Holdings AG (OTC: RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it ey...
Roche Targets Top Spot In Weight Loss Drug Market
Roche Holdings AG RHHBY on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes compe...
Roche (RHHBY) Reports Positive Trial Results for Breast Cancer Drug Portfolio
Roche (RHHBY) Reports Positive Trial Results for Breast Cancer Drug Portfolio
Roche moves obesity asset CT-388 into phase 3
Roche CEO, pharma execs to meet with Swiss government over US tariffs
Roche Chief Executive Thomas Schinecker and other senior executives from the Swiss pharmaceuticals industry will meet with the government on Monday to discuss the threat U.S. tariffs pose to the cruci...
Roche (RHHBY) Shares Rise on Positive Trial Results for Breast Cancer Drug
Roche (RHHBY) Shares Rise on Positive Trial Results for Breast Cancer Drug
Roche Holding AG (RHHBY) Special Call - Slideshow
2025-09-22. The following slide deck was published by Roche Holding AG in conjunction with this event.
Roche shares rise as firm advances experimental obesity drug to late-stage trial
Shares in Roche Holding rose around 2% on Monday, outperforming a broadly unchanged European healthcare index , as the drugmaker said it was advancing its experimental obesity drug CT-388 to a late-st...
Roche says breast cancer drug combo including giredestrant met main goals in late stage trial
Roche's Drug Candidate Meets Main Goals in Late-Stage Breast Cancer Study
The pharmaceutical company said that giredestrant in combination with everolimus significantly improved progression-free survival in patients with advanced breast cancer.
Genentech Reports Positive Results From Phase III EvERA Study
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III evERA study evaluating investigational giredestrant in combination with everolimus in people w...
Positive Phase III Results Show Genentech's Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating investigat...
Positive phase III results show Roche's giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
Basel, 22 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA study evaluating investigational giredestrant in combination with everolimus in ...
ASX 200 LIVE: ASX climbs, tracking Wall Street; Starpharma inks deal with Roche Group; Reece plans share buyback; Santos receives first gas in Barossa field.
ASX climbs, tracking Wall Street; Starpharma inks deal with Roche Group; Reece plans share buyback; Santos receives first gas in Barossa field. Follow live.
Key deals this week: Brighthouse Financial, Workday, Paramount Skydance, Radian Group, Roche and more
Discover this week’s biggest M&A deals across finance, tech, and healthcare sectors.
3 Potential Biotech Acquisition Targets
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go...
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio...
Roche Just Dropped $3.5 Billion on This Obesity-Linked Liver Drug--Here's Why Wall Street's Watching
Roche Just Dropped $3.5 Billion on This Obesity-Linked Liver Drug--Here's Why Wall Street's Watching